GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,898.50p
   
  • Change Today:
    -1.00p
  • 52 Week High: 1,909.73
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,075.43m
  • Volume: 5,055,181
  • Market Cap: £77,372m
  • RiskGrade: 129
  • Beta: 0.98

Latest ShareCast News

GSK chronic hepatitis B treatment hits goal in two studies

By Frank Prenesti

Date: Wednesday 07 Jan 2026

(Sharecast News) - GSK on Wednesday said its potential chronic hepatitis B treatment had met primary endpoints in two trials that covered 1,800 patients from 29 countries.

Japan approves GSK treatment for severe asthma

By Frank Prenesti

Date: Tuesday 06 Jan 2026

(Sharecast News) - GSK said Japan's Ministry of Health had approved its bronchial asthma treatment Exdensur after trial results showed "significant reductions" for patients with severe symptoms of the condition.

GSK's COPD treatment approved by Chinese regulators

By Benjamin Chiou

Date: Monday 05 Jan 2026

(Sharecast News) - Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD).

Director/PDMR Shareholding 22-Dec-2025 ShareCast
GSK to lower drug prices and expand access in US 22-Dec-2025 ShareCast
Transaction in Own Shares 22-Dec-2025 ShareCast
Transaction in Own Shares 19-Dec-2025 ShareCast
GSK asthma treatment approved by US regulators 17-Dec-2025 ShareCast
GSK secures MHRA nod for twice‑yearly resp... 16-Dec-2025 ShareCast
GSK gets preliminary nod for two respiratory dru... 12-Dec-2025 ShareCast
GSK's Arexy receives EU green light 12-Dec-2025 ShareCast
GSK's lung cancer drug granted orphan status by ... 10-Dec-2025 ShareCast
Berenberg raises target price on GSK 25-Nov-2025 ShareCast
GSK files suit against AnaptysBio over licensing... 21-Nov-2025 ShareCast
GSK posts better-than-expected Q3, upgrades guid... 29-Oct-2025 ShareCast
GSK lung cancer treatment gets EU orphan drug st... 28-Oct-2025 ShareCast
GSK shares lift on £268m prostate cancer deal 27-Oct-2025 ShareCast
GSK's Blenrep receives US FDA approval 24-Oct-2025 ShareCast
GSK advances low-carbon inhaler, halts latozinem... 22-Oct-2025 ShareCast
GSK reports positive trial data for oral cUTI tr... 21-Oct-2025 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,898.50p
Change Today -1.00p
% Change -0.05 %
52 Week High 1,909.73
52 Week Low 1,264.00
Volume 5,055,181
Shares Issued 4,075.43m
Market Cap £77,372m
Beta 0.98
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
6.98% above the market average6.98% above the market average6.98% above the market average6.98% above the market average6.98% above the market average
36.36% above the sector average36.36% above the sector average36.36% above the sector average36.36% above the sector average36.36% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 14
Sell 2
Strong Sell 0
Total 23
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q3 Q2
Ex-Div 13-Nov-25 14-Aug-25
Paid 08-Jan-26 09-Oct-25
Amount 16.00p 16.00p

Trades for 07-Jan-2026

Time Volume / Share Price
14:45 0 @ 1,893.00p
16:29 790 @ 1,898.20p
16:29 840 @ 1,898.50p
16:29 4 @ 1,898.50p
16:29 17 @ 1,898.50p

GSK Key Personnel

CEO Luke Miels

Top of Page